(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 30.73% in 21 sessions from €0.59 to €0.77 at 19:54 est on friday, after three consecutive sessions in a row of losses. cac 40 is sliding 1.78% to €7,187.27, following the last session's upward trend.
erytech pharma's last close was €0.82, 63.52% below its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-0.93.
more news about erytech pharma (eryp.pa).